Dataset Information


First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.

ABSTRACT: Introduction: As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 2018 to treat chronic hepatitis C patients.

Methods: This is an open-label, single arm study evaluating the effects of danoprevir boosted by ritonavir on treatment naïve and experienced COVID-19 patients for the first time. Patients received danoprevir boosted by ritonavir (100?mg/100?mg, twice per day). The primary endpoint was the rate of composite adverse outcomes and efficacy was also evaluated.

Results: The data showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. No patient had composite adverse outcomes during this study. After initiation of danoprevir/ritonavir treatment, the first negative reverse real-time PCR (RT-PCR) test occurred at a median of 2 days, ranging from 1 to 8 days, and the obvious absorption in CT scans occurred at a median 3 days, ranging from 2 to 4 days. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all enrolled 11 patients were discharged from the hospital.

Conclusion: Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.

PROVIDER: S-EPMC7710192 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC4862948 | BioStudies
| S-EPMC6783684 | BioStudies
| S-EPMC7368560 | BioStudies
| S-EPMC4400215 | BioStudies
| S-EPMC6783683 | BioStudies
| S-EPMC3910820 | BioStudies
| S-EPMC3122460 | BioStudies
| S-EPMC7834164 | BioStudies
| S-EPMC3486584 | BioStudies
| S-EPMC7251410 | BioStudies